Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
12 Agosto 2009 - 3:00AM
PR Newswire (US)
Stem Cell and Genomics Biosciences Company Signs Exclusive License
for C'elle(SM) Menstrual Stem Cell Technology in China HANGZHOU,
China, Aug. 11 /PRNewswire-FirstCall/ -- Cryo-Cell International,
Inc. (OTC:CCEL) (BULLETIN BOARD: CCEL) , one of the largest and
most established leaders in stem cell innovation today announced
that it has signed an exclusive license agreement with S-Evans
Biosciences, Inc. (SEB), a privately-held stem cell and genomics
technology company located near Shanghai in Hangzhou, Zhejiang
Province, People's Republic of China. The partnership will allow
S-Evans Biosciences to market and manufacture proprietary
C'elle(SM) menstrual stem cell technology including the processing
and storage of menstrual stem cells (MenSCs) exclusively throughout
mainland China. It will also allow SEB to conduct scientific
research studies using Cryo-Cell's proprietary C'elle(SM) menstrual
stem technology to identify future potential therapeutic
applications for a broad possible range of diseases that may affect
millions of people. The exclusive license agreement with SEB will
provide Cryo-Cell with future royalty fees from the processing and
annual storage of menstrual stem cells. SEB is a privately-held
company that collaborates with several institutions including
Zhejiang University; local hospitals; and Zhejiang-California
International Nanosystems Institute (ZCNI), a Sino-US co-founded
institute for biomedicine and nanotechnology research located on
Zhejiang University campus. In addition to SEB's business plans to
market and manufacture C'elle menstrual stem cells collected from
women across mainland China, the company expects to offer other
products and services associated with stem cell therapy; gene
testing and disease diagnosis (i.e. gene chips; high throughput
sequencings and standard molecular technologies). SEB expects to
receive funding from private agencies and the government for stem
cell research. In recent years, China has significantly increased
its efforts in the field of stem cell research and practice.
Currently, scientific research in the country primarily utilizes
bone marrow and embryonic stem cells. Clinical applications of stem
cells to treat conditions such as acute heart failure, acute liver
failure and lower limb ischemia have been reported by many
hospitals. A developing country with the largest population in the
world, China's estimated total population is 1.3 billion of which
women account for about half. SEB believes that the future market
opportunity for the C'elle service in China is potentially
significant. "Stem cell research and development is well-recognized
and fast-emerging in China. SEB believes that the innovative
proprietary technology of C'elle may provide women with the novel
opportunity to collect and cryopreserve their own stem cells that
have demonstrated considerable potential to be used in future
therapies and are easily harvest from a non-controversial source,"
stated Dr. Charlie Xiang, CEO of S-Evans Biosciences. "Through
SEB's expansive educational, scientific and medical affiliations,
we anticipate that there may possibly be enormous potential
opportunity to successfully market the compelling and highly
differentiated quality service of C'elle. We are also eager to
explore prospective opportunities with Cryo-Cell to collaborate on
research and development of future potential stem cell therapies
that may utilize this breakthrough technology." "We are
particularly interested in supporting research on stem cells and
genomics that may contribute a great deal to improve our life
quality and human health", added by Mr. Guojian Shen, chairman of
the Pele Group that invested in S-Evans Biosciences. The strategic
partnership between Cryo-Cell International and S-Evans Biosciences
comes at an excellent time for healthcare in China. The Chinese
government has announced a new healthcare reform plan that is
expected to allocate considerable resources towards stem cell
research and development. The government also considers women's
health an area of priority and has continued to support expansion
and improvement of women's healthcare services and institutes
throughout the country. "We are both honored and excited to partner
with distinguished professor and CEO Dr. Xiang and his colleagues
at S-Evans Biosciences to operationalize their license of
Cryo-Cell's proprietary C'elle menstrual stem cell technology. We
anticipate that C'elle will provide the opportunity for women
across mainland China to harvest and cryopreserve their own stem
cells for potential therapeutic utilization in the future," said
Mercedes A. Walton, Cryo-Cell's Chairman and CEO. "We are clearly
encouraged by the overall pace of clinical advances in stem cell
therapeutic development underway in China. We share SEB's belief
that there may possibly be a vast pipeline of potential opportunity
to collaborate on the possible development of future therapies
using menstrual stem cell technology." The C'elle service is based
on Cryo-Cell's expansive patent pending IP technology portfolio and
was introduced in November, 2007 as the first and only service that
empowers women to collect and cryopreserve menstrual flow
containing undifferentiated adult stem cells for future potential
utilization by the donor or possibly first-degree relatives in a
manner similar to umbilical cord blood stem cells. Based on the
continued success of MenSCs in the research setting, Cryo-Cell is
seeking to actively expand global C'elle technology licensing, in
addition to building its portfolio of research collaborations with
world renowned scientists committed to study this novel stem cell
population for a broad range of regenerative therapeutic
development. About S-Evans Biosciences Privately-held company (SEB)
was registered in 2009 in Hangzhou, Zhejiang Province, People's
Republic of China. Invested by the Pele Group
http://www.pele.net.cn/, SEB collaborates with ZCNI, Zhejiang
University and affiliated hospitals. Products and services:
processing and storage of menstrual stem cells; stem cell therapy;
gene testing and disease diagnosis (gene chips, high throughput
sequencing and standard molecular technologies). For more
information contact: . About C'elle The C'elle(SM) service was
introduced in November 2007 as the first and only service that
empowers women to collect and cryopreserve menstrual flow
containing undifferentiated adult stem cells for future utilization
by the donor or possibly their first-degree relatives in a manner
similar to umbilical cord blood stem cells. For more information,
visit http://www.celle.com/. About Cryo-Cell International, Inc.
(OTCBB: CCEL.OB) Based in Oldsmar, Florida, with nearly 185,000
clients worldwide, Cryo-Cell is one of the largest and most
established family cord blood banks. ISO 9001:2000 certified and
accredited by the AABB, Cryo-Cell operates in a state-of-the-art
Good Manufacturing Practice and Good Tissue Practice
(cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded
company. OTC Bulletin Board Symbol: CCEL. For more information,
please call 1-800-STOR-CELL (1-800-786-7235) or visit
http://www.cryo-cell.com/. Forward-Looking Statement Statements
wherein the terms "believes", "intends", "projects" or "expects" as
used are intended to reflect "forward-looking statements" of the
Company. The information contained herein is subject to various
risks, uncertainties and other factors that could cause actual
results to differ materially from the results anticipated in such
forward-looking statements or paragraphs, many of which are outside
the control of the Company. These uncertainties and other factors
include the uncertainty of market acceptance of any potential
service offerings relating to types of stem cells other than cord
blood stem cells, including the C'elle service, given that
menstrual stem cells and other new stem cells have not yet been
used in human therapies, and treatment applications using such stem
cells may not be developed and commercialized; or if they are not
likely to be developed or commercialized for many years and are
subject to further research and development; the need for
additional development and testing before determining the ultimate
commercial value of the Company's intellectual property relating to
the menstrual stem cells; the need to complete certain
developments, including completion of clinical validation and
testing, before any new process other than C'elle can be
commercialized, and the Company's development of its final business
and economic model in offering any such service; any adverse effect
or limitations caused by recent increases in government regulation
of stem cell storage facilities; any risks or uncertainties
associated with conducting business in the People's Republic of
China; any increased competition in our business; any decrease or
slowdown in the number of people seeking to store stem cells or
decrease in the number of people paying annual storage fees; any
technological breakthrough or medical breakthrough that would
render the Company's business of stem cell preservation obsolete;
and any other risk factors described in our filing with the
Securities and Exchange Commission. The foregoing list is not
exhaustive, and the Company disclaims any obligations to
subsequently revise any forward-looking statements to reflect
events or circumstances after the date of such statements. Readers
should also carefully review the risk factors described in other
documents the Company files from time to time with the Securities
and Exchange Commission, including the most recent Annual Report on
Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current
Reports on Form 8-K filed by the Company. Contact: General Media
Inquiries Kristin Boza 312-233-1295 Financial Media Inquiries:
Cryo-Cell International, Inc. Investor Relations Dianne Will
518-398-6222 DATASOURCE: Cryo-Cell International, Inc. CONTACT:
General Media Inquiries, Kristin Boza, +1-312-233-1295, , for
Cryo-Cell International, Inc.; or Financial Media Inquiries,
Cryo-Cell International, Inc., Investor Relations, Dianne Will,
+1-518-398-6222,
Copyright